Abstract
The prevalence of type 2 diabetes is rising at an alarming rate worldwide. Coronary artery disease (CAD) is the leading cause of morbidity and mortality in the diabetic population. Future CAD risk should be routinely assessed in patients with diabetes as specific subgroups might benefit from information derived from cardiac stress testing and other diagnostic procedures. Risk factor control is of paramount importance in all cases and it usually requires sustained lifestyle modifications, coupled with pharmacological interventions. Statins and angiotensin-converting enzyme (ACE) inhibitors are the first-line agents for the treatment of dyslipidaemia and hypertension, respectively. Microvascular, but not macrovascular, complications of diabetes are effectively prevented by good glycaemic control. Metformin is considered the first-choice agent in overweight diabetic subjects, while the role of thiazolidinediones is currently the focus of medical research. The diagnosis of acute coronary events in patients with diabetes is often challenging because of the high prevalence of silent ischaemia in these subjects. All acute cardiac events need to be promptly treated and myocardial reperfusion attempted without delay. Maintaining glucose levels as close to normal as possible, during and shortly after an acute event, improves prognosis in patients with diabetes. Risk factor control remains the cornerstone of secondary prevention; beta-blockers, ACE-inhibitors and antiplatelet agents confer additional symptomatic and survival benefit. Similar therapeutic principles also apply to patients with type 1 diabetes. This article addresses the complex problem of managing patients with diabetes and coronary artery disease.
Keywords: Type 2 diabetes mellitus, coronary artery disease, risk stratification, primary prevention, thiazolidinediones
Current Pharmaceutical Design
Title: Medical Management of the Diabetic Patient with Coronary Artery Disease
Volume: 14 Issue: 25
Author(s): Kalypso Karastergiou and Juan Carlos Kaski
Affiliation:
Keywords: Type 2 diabetes mellitus, coronary artery disease, risk stratification, primary prevention, thiazolidinediones
Abstract: The prevalence of type 2 diabetes is rising at an alarming rate worldwide. Coronary artery disease (CAD) is the leading cause of morbidity and mortality in the diabetic population. Future CAD risk should be routinely assessed in patients with diabetes as specific subgroups might benefit from information derived from cardiac stress testing and other diagnostic procedures. Risk factor control is of paramount importance in all cases and it usually requires sustained lifestyle modifications, coupled with pharmacological interventions. Statins and angiotensin-converting enzyme (ACE) inhibitors are the first-line agents for the treatment of dyslipidaemia and hypertension, respectively. Microvascular, but not macrovascular, complications of diabetes are effectively prevented by good glycaemic control. Metformin is considered the first-choice agent in overweight diabetic subjects, while the role of thiazolidinediones is currently the focus of medical research. The diagnosis of acute coronary events in patients with diabetes is often challenging because of the high prevalence of silent ischaemia in these subjects. All acute cardiac events need to be promptly treated and myocardial reperfusion attempted without delay. Maintaining glucose levels as close to normal as possible, during and shortly after an acute event, improves prognosis in patients with diabetes. Risk factor control remains the cornerstone of secondary prevention; beta-blockers, ACE-inhibitors and antiplatelet agents confer additional symptomatic and survival benefit. Similar therapeutic principles also apply to patients with type 1 diabetes. This article addresses the complex problem of managing patients with diabetes and coronary artery disease.
Export Options
About this article
Cite this article as:
Karastergiou Kalypso and Kaski Carlos Juan, Medical Management of the Diabetic Patient with Coronary Artery Disease, Current Pharmaceutical Design 2008; 14 (25) . https://dx.doi.org/10.2174/138161208786071272
DOI https://dx.doi.org/10.2174/138161208786071272 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Potentials of Uncariae Ramulus Cum Uncis for the Treatment of Migraine: Targeting CGRP in the Trigeminovascular System
Current Neuropharmacology Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Role of 1,4-Benzothiazine Derivatives in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction
Current Pharmaceutical Design Safety and Efficacy of Adenovirus Carrying Hepatocyte Growth Factor Gene by Percutaneous Endocardial Injection for Treating Post-infarct Heart Failure: A Phase IIa Clinical Trial
Current Gene Therapy Stem Cell Gene Therapy for Chronic Renal Failure
Current Gene Therapy The Effect of Local Alcohol Delivery in Reducing Intimal Hyperplasia Induced by Vascular Injury and the Clinical Implications
Vascular Disease Prevention (Discontinued) Hydrogen Gas as an Exotic Performance-Enhancing Agent: Challenges and Opportunities
Current Pharmaceutical Design Relaxin in Vascular Physiology and Pathophysiology: Possible Implications in Ischemic Brain Disease
Current Neurovascular Research Anti-Metastatics: An Overview of Drug Candidates in Current Pipelines
Current Pharmaceutical Design Nephro-Protective Effect of Cortex Lycii Radicis Extracts in Streptozotocin- Induced Diabetic Rats
Current Signal Transduction Therapy Hyponatraemia Associated with Trimethoprim Use
Current Drug Safety Nitrones: A Potential New Alternative as Therapeutic Agents
Current Organic Chemistry Investigating Drug Repositioning Approach to Design Novel Prodrugs for Colon-specific Release of Fexofenadine for Ulcerative Colitis
Current Drug Delivery Potential of Resveratrol in Preventing the Development of Heart Failure
Current Chemical Biology Role of COL4A1 in Basement-Membrane Integrity and Cerebral Small-Vessel Disease. The COL4A1 Stroke Syndrome
Current Medicinal Chemistry Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Current Pharmaceutical Design Editorial [Hot topic: Anti-Angiogenic Agents (Executive Editor: Maurizio Botta and Anna Di Donna)]
Current Pharmaceutical Design Examination of QTc Values in Critically Ill Patients Diagnosed with Delirium and Prescribed Atypical Antipsychotics
Current Drug Safety Intra-arterial Instillation of a Nociceptive Agent Modulates Cardiorespiratory Parameters Involving 5-HT3 and TRPV1 Receptors in Anesthetized Rats
Cardiovascular & Hematological Disorders-Drug Targets